The biology of oncogenesis and the molecular mechanisms of GBM have showed that it typically overexpresses vascular endothelial growth factor, which can promote tumor angiogenesis, contributing to tumor growth and progression.[8] Therefore, antiangiogenic therapy seems to be an attractive therapeutic strategy. The gene discussed is VEGFA; the disease is glioblastoma.